[Form 3] CASI Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership

CASI Pharmaceuticals, Inc. Chief Operating Officer Wang Chunhua filed an initial ownership report detailing existing option holdings in CASI ordinary shares.

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. Chief Operating Officer Wang Chunhua filed an initial ownership report detailing existing option holdings in CASI ordinary shares. The filing lists multiple options to buy shares at exercise prices of $1.93, $2.67 and $5.78, with expirations ranging from 2028 through 2034.

According to a footnote, all of these options are fully vested and exercisable as of the date of the form, meaning they can already be converted into ordinary shares subject to their terms. The report reflects holdings rather than new purchases or sales.

Insider Trade Summary

14 transactions reported

Mixed 14 txns

Insider Wang Chunhua

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--
holding	Option (right to buy)	--	--	--

Holdings After Transaction: Option (right to buy) — 235,000 contracts (Direct)

Footnotes (1)

1. F1. The options are fully vested and exercisable as of the date of this form.

Key Figures

Option grant: 20,000 shares at $1.93 Option grant: 7,500 shares at $2.67 Option grant: 30,000 shares at $5.78 +1 more

4 metrics

Option grant 20,000 shares at $1.93 Option to buy CASI ordinary shares, expiration in 2028

Option grant 7,500 shares at $2.67 Option to buy CASI ordinary shares, expiration in 2034

Option grant 30,000 shares at $5.78 Option to buy CASI ordinary shares, expiration in 2034

Fully vested options All reported options Footnote states options are fully vested and exercisable

Key Terms

Form 3, Option (right to buy, exercise price, fully vested and exercisable

4 terms

Form 3 regulatory

"Chief Operating Officer Wang Chunhua filed an initial ownership report on Form 3."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Option (right to buy financial

"The filing lists each security title as "Option (right to buy)" over ordinary shares."

exercise price financial

"Several option positions show an exercise price of $1.93, $2.67 or $5.78 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully vested and exercisable financial

"A footnote explains the options are fully vested and exercisable as of the form date."

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wang Chunhua

(Last) (First) (Middle)

1701, CHINA CENTRAL OFFICE TOWER 1

NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT

(Street)

BEIJING 100025

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	03/19/2028	Ordinary Share	20,000	$1.93	D
Option (right to buy)	(1)	01/09/2030	Ordinary Share	8,000	$1.93	D
Option (right to buy)	(1)	01/27/2031	Ordinary Share	2,000	$1.93	D
Option (right to buy)	(1)	08/16/2031	Ordinary Share	40,000	$1.93	D
Option (right to buy)	(1)	08/16/2031	Ordinary Share	20,000	$1.93	D
Option (right to buy)	(1)	08/16/2031	Ordinary Share	40,000	$1.93	D
Option (right to buy)	(1)	05/12/2033	Ordinary Share	16,667	$1.93	D
Option (right to buy)	(1)	06/18/2034	Ordinary Share	7,500	$2.67	D
Option (right to buy)	(1)	11/06/2034	Ordinary Share	30,000	$5.78	D
Option (right to buy)	(1)	11/06/2034	Ordinary Share	20,000	$5.78	D
Option (right to buy)	05/12/2026	05/12/2033	Ordinary Share	8,333	$1.93	D
Option (right to buy)	06/18/2026	06/18/2034	Ordinary Share	7,500	$2.67	D
Option (right to buy)	06/18/2027	06/18/2034	Ordinary Share	7,500	$2.67	D
Option (right to buy)	06/18/2028	06/18/2034	Ordinary Share	7,500	$2.67	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

	/s/ Chunhua Wang	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)